Jed A. Latkin
2019
In 2019, Jed A. Latkin earned a total compensation of $739.9K as Chief Executive Officer, Chief Operating Officer and Chief Financial Officer at Navidea Biopharmaceuticals, a 16% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $178,143 |
|---|---|
| Option Awards | $81,200 |
| Salary | $475,000 |
| Other | $5,600 |
| Total | $739,943 |
Latkin received $475K in salary, accounting for 64% of the total pay in 2019.
Latkin also received $178.1K in non-equity incentive plan, $81.2K in option awards and $5.6K in other compensation.
Rankings
In 2019, Jed A. Latkin's compensation ranked 10,512th out of 13,971 executives tracked by ExecPay. In other words, Latkin earned more than 24.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,512 out of 13,971 | 25th |
Division Manufacturing | 4,242 out of 5,692 | 26th |
Major group Chemicals And Allied Products | 1,639 out of 2,189 | 25th |
Industry group Drugs | 1,404 out of 1,875 | 25th |
Industry In Vitro and In Vivo Diagnostic Substances | 45 out of 77 | 42nd |
Source: SEC filing on July 31, 2020.
Latkin's colleagues
We found two more compensation records of executives who worked with Jed A. Latkin at Navidea Biopharmaceuticals in 2019.
News
Navidea Biopharmaceuticals CEO Jed Latkin's 2021 pay rises 10% to $1.3M
October 24, 2022
Navidea Biopharmaceuticals CEO Jed Latkin's 2020 pay jumps 66% to $1.2M
August 2, 2021
Navidea Biopharmaceuticals CEO Jed Latkin's 2019 pay rises 16% to $740K
July 31, 2020
Navidea Biopharmaceuticals CEO Michael Goldberg's 2018 pay jumps 76% to $1.5M
June 28, 2019